Kawasaki, Japan, Feb 10, 2010 - (ACN Newswire) - Fujitsu Laboratories Ltd. and the University of Toronto today announced their joint development of a new processing method for transceiver chips used in gigabit-class(1) high-speed data transmission over wirelines. The new technology employs digital circuitry to replace previously-required structures that used analog circuits. While analog processing require circuits that are adapted to the specifications of a signal being transmitted, such as transmission distance and amplitude, this new digital approach can perform these optimizations automatically, so that a single circuit could be used to accommodate a wide range of various wireline communications. Compared to conventional processing methods, this new digital-processing method makes it possible to shorten development periods by approximately half. It is anticipated that this new technology in the future could be applied to a variety of wireline communication applications, including 10 Gbps high-speed Ethernet in datacenters.
Details of this technology were presented at the IEEE International Solid-State Circuits Conference 2010 (ISSCC 2010) being held in San Francisco from February 7-11. (Presentation number: 8.7)
Background and Technological Challenges
File size data volumes for large photographic, audio, and video files are becoming increasingly larger, thus requiring a significant amount of bandwidth to transmit, leading to demand for ever-faster wireline data communications. Conventional transceiver chips rely on analog circuitry which needs to be optimized to accommodate specifications of the signal being transmitted - such as transmission distance and amplitude - and therefore require multiple transceiver chips to be designed in order to accommodate for various applications.
With a growing diversity of devices featuring high-speed data transmission, the need to optimize an existing technology for every new type of device or model has become a bottleneck in the development process. Efforts to develop transceiver chips within short development periods that can accommodate the wide range of different devices have been proven challenging.
Newly-developed Technology
Fujitsu Laboratories and the University of Toronto have developed a digital circuit-based transceiver chip. Featuring digital circuitry, the new transceiver chip can automatically optimize itself for a variety of high-speed communications circuits, thus significantly reducing development periods by approximately half compared with conventional methods.
This technology detects variations in the delay on the time axis of the input signal, caused during data transmission, and based on that can automatically adjust the timing it uses for judging whether an incoming signal is a 0 or 1 (Figure 1). Since variations in data transmissions increase along with faster transmission speeds, this new technology is essential for accurate data exchange. This is the world's first technology to achieve Gbps-class speeds without the use of analog circuitry elements, while offering fully-digital timing adjustments for signal-determination.
Results
As a world's first, by using digital circuitry-based high-speed transceiver technology, Fujitsu Laboratories and the University of Toronto's new technology makes it possible to reduce the design and development period for a gigabit-class transceiver chip by approximately one-half (1/2) compared with conventional methods. This suggests that transceiver chips for a wide range of communications devices could be offered in a timely manner.
Future Developments
Fujitsu Laboratories and the University of Toronto will continue with development of this technology to optimize the digital signal processing, to further reduce the transceiver's power consumption.
Glossary and Notes
1 Gigabit-class/Gigabits-per-second (Gbps):Gigabits-per-second (Gbps) expresses data rate and indicates how many gigabits can be transferred per second. 10 Gbps is 10 billion bits-per-second (10 billion bps) = 10,000 megabits-per-second (10,000 Mbps), and indicates that 10 billion bits of data can be transferred per second.
About University of Toronto
Established in 1827, the University of Toronto is Canada's largest university, recognized as a global leader in research and teaching. U of T's distinguished faculty, institutional record of groundbreaking scholarship and wealth of innovative academic opportunities continually attract outstanding students and academics from around the world. U of T is committed to providing a learning experience that benefits from both a scale almost unparalleled in North America and from the close-knit learning communities made possible through its college system and academic divisions. Located in and around Toronto, one of the world's most diverse regions, U of T's vibrant academic life is defined by a unique degree of cultural diversity in its learning community. The University is sustained environmentally by three green campuses, where renowned heritage buildings stand beside award-winning innovations in architectural design.
For more information: http://www.utoronto.ca/
About Fujitsu Ltd
Fujitsu is a leading provider of IT-based business solutions for the global marketplace. With approximately 160,000 employees supporting customers in 70 countries, Fujitsu combines a worldwide corps of systems and services experts with highly reliable computing and communications products and advanced microelectronics to deliver added value to customers. Headquartered in Tokyo, Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.6 trillion yen (US$47 billion) for the fiscal year ended March 31, 2009. For more information, please visit www.fujitsu.com.
Contact: Fujitsu Laboratories Ltd. Design Solutions Lab. Platform Technologies Lab. Tel: +81-44-754-2635 E-mail:hsio_adc_pr@ml.labs.fujitsu.com University of Toronto Prof. Ali Sheikholeslami Dept. of Electrical and Computer Engineering Tel: +1(416)978-1681 E-mail:ali@eecg.utoronto.ca Address: 10 King's College Road, Toronto, Ontario, M5S 3G4
Copyright 2010 ACN Newswire. All rights reserved.
Kawasaki, Japan, Feb 10, 2010 - (ACN Newswire) - Fujitsu Laboratories Limited and the University of Toronto today announced that they have jointly developed the world's first high-reliability read-method for use with spin-torque-transfer (STT) MRAM(1) that is insusceptible to erroneous writes. STT MRAM is regarded as a potential future form of non-volatile memory(2) that could be used as an alternative to flash memory. NOR flash memory that is embedded in microcontrollers widely used in mobile phones and other electronic devices is expected to reach the limits of its feasible miniaturization in the near future, which has led to the search for an alternative low-power non-volatile memory that will allow continued necessary miniaturization. By resolving one of the major obstacles to using STT MRAM, Fujitsu and the University of Toronto's new read-method marks a major step towards the practical implementation of STT MRAM as a necessary replacement for flash memory, in view of future requirements that will be necessary for compact and low-power electronic devices.
Details of this technology were presented at the IEEE International Solid-State Circuits Conference 2010 (ISSCC 2010) being held in San Francisco from February 7-11. (Presentation number: 14.1)
Background
Many electronic devices such as mobile phones or PDAs use microcontrollers with embedded flash memory, which allows onboard software to be rewritten. However, NOR flash memory used in such microcontrollers is nearing the physical limits of its miniaturization, which has led to research on various types of memory that could replace NOR flash memory.
STT MRAM, which uses magnetic materials as the memory storage element, is gaining attention as an emerging potential candidate to replace flash memory, as STT MRAM meets the needs for speed, low power consumption, and miniaturization that would make it a good candidate to replace flash memory.
Technological Challenges
STT MRAM uses memory storage elements that take advantage of the effect in which a current that is passed through a magnetic material - such as a magnetic tunnel junction (MTJ)(3) - reverses its direction of magnetization (Figure 1). Passing a current through the MTJ causes its direction of magnetization to switch between a parallel or anti-parallel state, which has the effect of switching between low resistance and high resistance. Because this can be used to represent the 1s and 0s of digital information, STT MRAM can be used as a non-volatile memory.
Reading STT MRAM involves applying a voltage to the MTJ to discover whether the MTJ offers high resistance to current ("1") or low ("0"). However, a relatively high voltage needs to be applied to the MTJ to correctly determine whether its resistance is high or low, and the current passed at this voltage leaves little difference between the read-current and the write-current. Any fluctuation in the electrical characteristics of individual MTJs could cause what was intended as a read-current, to have the effect of a write-current, thus reversing the direction of magnetization of the MTJ.
Newly-developed Technology
In a joint collaboration, Fujitsu Laboratories and the University of Toronto have developed an innovative circuit design (Figure 3) that for the first time resolves the issue of erroneous writes in STT MRAM during read operations.
The newly developed read-method uses a negative resistance(4) that is intermediate between the MTJ's high resistance and low resistance on a parallel circuit (Figure 4). If the MTJ is in a high-resistance state, this circuit exhibits negative-resistance characteristics. If the MTJ is in a low-resistance state, then it exhibits normal-resistance characteristics. These characteristics allow the resistance value to be read at lower voltages than before, suppressing the tendency of the read operation to reverse the direction of magnetization and avoiding the problem of erroneous write operations.
Results
The development of this new read circuit with negative resistance has resulted in STT MRAM that is insusceptible to erroneous writes caused by fluctuations in the electrical characteristics of the MTJs. It is anticipated that the STT MRAM used as miniaturized non-volatile memory would enable greater high-performance in mobile phones and other electronic devices.
Future Developments
Fujitsu Laboratories and the University of Toronto plan to continue with R&D related to STT MRAM to strive toward practical implementation, such as lowering write currents and developing process technologies for further miniaturization.
Glossary and Notes
1 Spin- Torque-Transfer MRAM:Spin-torque-transfer magnetoresistive (STT) random access memory. MRAM that uses the "spin-torque-transfer" effect to reverse the direction of magnetization of an element by passing current through it.
2 Non-volatile memory:Memory that persists even when electrical power is cut.
3 Magnetic tunnel junction (MJT):A tunnel junction that uses the magnetoresistive effect. Consists of a recording layer made of ferromagnetic material, an insulating film a few atoms thick, and a layer made of ferromagnetic material that will not change its direction of magnetization in the presence of a current.
4 Negative resistance:An element that has negative resistance value, in which its current decreases when voltage rises.
About University of Toronto
Established in 1827, the University of Toronto is Canada's largest university, recognized as a global leader in research and teaching. U of T's distinguished faculty, institutional record of groundbreaking scholarship and wealth of innovative academic opportunities continually attract outstanding students and academics from around the world. U of T is committed to providing a learning experience that benefits from both a scale almost unparalleled in North America and from the close-knit learning communities made possible through its college system and academic divisions. Located in and around Toronto, one of the world's most diverse regions, U of T's vibrant academic life is defined by a unique degree of cultural diversity in its learning community. The University is sustained environmentally by three green campuses, where renowned heritage buildings stand beside award-winning innovations in architectural design.
For more information: http://www.utoronto.ca/
About Fujitsu Ltd
Fujitsu is a leading provider of IT-based business solutions for the global marketplace. With approximately 160,000 employees supporting customers in 70 countries, Fujitsu combines a worldwide corps of systems and services experts with highly reliable computing and communications products and advanced microelectronics to deliver added value to customers. Headquartered in Tokyo, Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.6 trillion yen (US$47 billion) for the fiscal year ended March 31, 2009. For more information, please visit www.fujitsu.com.
Contact: Fujitsu Laboratories Ltd. Technology Integration Lab. Platform Technologies Lab. Tel: +81(46)250-8379 E-mail:til-si@ml.labs.fujitsu.com University of Toronto Prof. Ali Sheikholeslami Dept. of Electrical and Computer Engineering Tel: +1(416)978-1681 E-mail:ali@eecg.utoronto.ca Address: 10 King's College Road, Toronto, Ontario, M5S 3G4 Canada
Copyright 2010 ACN Newswire. All rights reserved.
NEW YORK, Feb. 10 /PRNewswire/ -- Bachelorette star Jillian Harris sat down with 24Savvy.com in her Chicago home to talk about sex and money, her famous hot dog theory, the in-laws, and the challenges of planning a wedding.
"I'm kind of a guy in the way that I don't actually care if I ever have a wedding," Jillian told host Kathleen Monteleone in 24Savvy.com's newest webisode, debuting today.
24Savvy.com is the new online destination for sharing tips and ideas to live a smarter, more creative life. 24Savvy.com also serves as a social community where users are encouraged to interact on every level, including commenting, voting, blogging, posting video and photos. All activities earn members points towards great prizes and the chance to opt-in for savvy gifts.
Jillian told 24Savvy.com it has been important to keep her relationship moving at a pace that is right for her. "One of the biggest things we need to accomplish is to slow down, which we don't know how to do, and I would love to learn how to do that better," Jillian said of her 2010 goals with fiance Ed Swiderski. "All my friends and family are really pushing for us to set a date and to plan the wedding, and it gets us excited, but then we're like, 'Wait, our life has moved so fast. Are we in a rush for this?'"
Jillian, who is working on a book about her hot dog theory for finding the right guy, said she hopes an iPhone app will be the next step. "How cool would this be? You see a guy putting mustard and sauerkraut and onions on his dog, in that order, you type it into your iPhone, and bling! It tells you if he's dateable or if you guys are compatible."
Jillian Harris is the featured guest this month on the 24Savvy.com webisode series. A new webisode will debut each Monday through March 1, featuring savvy tips on relationships, sex, the in-laws, and how to make a relationship last.
Previous 24Savvy.com webisodes have featured Margaret Colin of "Gossip Girl" and ongoing Oprah contributors Joe Lupo and Jesse Garza of Visual Therapy.
ABOUT 24/SAVVY
24/Savvy (www.24savvy.com) is a multimedia digital community dedicated to providing members with tools for savvier living. With editorial content, style news and reviews, gift giveaways and a webisode series produced by award-winning production company Mountain Lion Entertainment, 24/Savvy is the new online destination for living a smarter, more creative life.
Company founder Valerie Donati said, "A savvy mindset isn't about trading down, but trading off.
Savvy doesn't necessarily equal thrift, it just means playing it smart. 24/Savvy gives its members fun and inventive ways to live their smartest, most creative life, regardless of their income."
24/Savvy, It's About Your Lifestyle. Not Your Bank Balance.
SOURCE 24Savvy.com
- Testosterone Phase II(b) Clinical Trial Nearing Completion
- Acquisition of Second Technology Platform
- Private Placement Recently Closed
TORONTO, Feb. 10 /PRNewswire/ - Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives. Trimel is now well positioned with multiple Localized Dosing Technology (LTD) platforms, a robust and rapidly advancing product pipeline, a dedicated facility to meet its clinical development and manufacturing requirements and has ready access to capital to meet its financial needs as it executes its Business Plan.
Testosterone Phase II(b) Clinical Trial Nearing Completion
Trimel BioPharma Holdings Inc. is developing a product to treat male hypogonadism (or "Low T"). Hypogonadism is a biochemical syndrome characterized by a deficiency in serum testosterone that can be either acquired or inherited and seriously affects the quality of life for those afflicted with the syndrome. Trimel's developmental product for hypogonadism is delivered utilizing a Bio-Adhesive Gel Nasal Deposit System. This unique delivery systems avoids transference issues that are associated with the current topical gel therapies and provides portability which is a significantly more convenient dosing regime versus most other products currently available in the marketplace.
Trimel's hypogonadism product, Compleo - which in Latin means "to bring man up to strength", is being developed initially for the North American and European markets. Sales of currently available treatments for hypogonadism in North America approximate $1 billion, where the estimated treatment ratio is only 10% of those afflicted, and the European market is approximately half the size the North American market.
Earlier this quarter, the ongoing Phase II(b) clinical trial for Compleo closed its input screening and it is expected that all subjects will complete dosing by the end of the quarter. No serious Adverse Events have been reported and early data indicates that the product is efficacious and meets the Food and Drug Administration's (FDA) clinical endpoints.
Trimel has exclusive rights to employ the Bio-Adhesive Gel Nasal Deposit System in four specific treatment areas including testosterone for males (above), in the Female Sexual Dysfunction therapeutic class where statistics reveal that 43% of women between the age of 18 and 59 suffer from various symptoms, for Parkinsonism and for an anxiety agent for the treatment of acute panic breakthrough disorder.
Second Technology Platform Acquired
In December of 2009, Trimel successfully acquired through the complete asset purchase of enabling technologies from Direct Haler A/S, a privately held Danish company. These technologies received the European Drug Delivery Devices Product Differentiation Innovation of the Year Award from Frost Sullivan for 2009. These technologies are focused on the delivery of pharmaceutical compounds through pulmonary inhalation and nasal dispersion systems that utilize unique patented dosing technologies. These technologies are applicable to numerous pharmaceutical compounds covering a wide variety of therapeutic classes.
These technologies provide patients with improved uptake of medication over current therapies. Key features of these technologies are: a) the Product dose is visible within the device and therefore patients can be assured that their required dose has been delivered; b) the dosage device is disposable and therefore there is no risk of re-infection; and c) the dose is deposited at the site of action which avoids many of the side effects associated with certain classes of drugs.
As part of the acquisition, Trimel has acquired three product candidates that are in clinical development. These product candidates are being developed to provide patients suffering from allergy or asthma with a unique treatment modality to dramatically improve their quality of life. Trimel is also exploring other product candidates in the areas of pain management and supportive cancer therapy.
Completion of Private Placement
Trimel recently completed an initial round of private equity financing. This financing was achieved through a limited offering that was only made available to Friends and Family and a very limited number of select exempt investors. The Company, through this offering, successfully raised over $4.5 million in new capital. Investors, including the Company's founder, have contributed approximately $18 million to the Company since inception, and this capital has enabled the Company to make the significant advancements as outlined above.
About Trimel
Trimel BioPharma Holdings Inc. is a privately held company focused on improving the utility of known pharmaceutical compounds by employing 21st century dosing technologies that are specifically designed to avoid first pass metabolism. These Localized Dosing Technologies (LDT) allow Trimel to precisely target the distribution of medication thereby circumventing the gastrointestinal tract and liver to improve patient outcomes and reduce side effects.
Trimel currently has three proprietary LDT platforms and is actively pursuing the development and application of these technologies with several high value high volume pharmaceutical compounds.
For media inquiries, please contact Bruce Brydon or Ken Howling at ir@trimelbiopharma.com or 416 679 0771.
For licensing inquiries, please contact John McCleery at johnmccleery@trimel.net.
Caution Regarding Forward-Looking Information and "Safe Harbor" Statement
All statements, other than statements of historical facts, made in this press release are forward-looking statements and may be forward-looking information in accordance with applicable securities laws (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, the Company's objectives, goals, strategies, beliefs, intentions, plans, estimates, and outlook, including, without limitation, statements concerning the following:
- the state of the Company's product pipeline;
- the prospective benefits of product candidates in clinical
development;
- the number of subjects and timing of completion of dosing in respect
of the ongoing Phase II(b) clinical trials for Compleo.
Forward-looking statements are identified by words such as "believe", "anticipate", "estimate", "expect", "intend", "plan", "expect", "project", "may" and "will" and other similar expressions. Although not all forward-looking statements contain these identifying words, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Although the Company has indicated certain of these statements set out herein, all of the statements in this press release that contain forward-looking statements are qualified by these cautionary statements.
Although the Company believes that the expectations reflected in any forward-looking statements made in this press release are reasonable, actual results may differ materially from those expressed, or implied, in such statements. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to assumptions regarding: the regulatory and legislative environment; general commercial risks; the ability of the Corporation to establish and maintain a market for the Company's products; market and consumer acceptance; operations; profitability; the Company's reliance on third parties; attraction and retention of key employees and consultants; competition; intellectual property; product development; availability of raw materials; inventory valuation, obsolescence and spoilage; health and safety risks; information; acquisition of companies, assets or technologies; availability of credit; investment, borrowing and interest rates; and liability insurance.
Important risks and factors that could cause actual results to differ materially from expectations include: (a) that the Company is a start-up business with no demonstrated history of profitable operations and accordingly (i) there is uncertainty regarding the ability of the Company to ever achieve, sustain or increase profitability, and (ii) there is no assurance the Company will be able to fund its operations with existing capital, or that it will be able to raise additional capital to fund operations; (b) the Company's dependence on, and ability to attract and retain, key personnel; (c) that the Company is under the control of a single controlling shareholder; (d) the cost of any future acquisitions and the ability to integrate any acquired businesses; (e) contractual disagreements and negotiations with third parties; (f) difficulties obtaining necessary approvals for development of products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; (g) the results of continuing and future safety and efficacy studies by industry and government agencies; (h) uncertainties associated with the development, acquisition and launch of new products; (i) acceptance and demand for new pharmaceutical products; (j) the impact of competitive products and pricing; (k) the availability of raw materials and finished products; (l) the unpredictability of protection afforded by any patents or other intellectual and proprietary property; (m) any claims for infringement of the intellectual property rights of others; (n) potential product liability; (o) reliance on key strategic alliances; (p) the general regulatory environment; (q) tax rate assumptions; (r) the outcome of legal proceedings; and (s) fluctuating operating results. The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. The Company does not undertake to update or revise any forward-looking statements, except as may be required by law.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and no offering of securities is currently being made or is intended.
SOURCE Trimel BioPharma Holdings Inc.
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/894941/1q10_poland_mobile) has announced the addition of IE Market Research Corp.'s new report "1Q10 Poland Mobile Operator Forecast, 2009 - 2014: Poland will have 51.5 million mobile subscribers in 2014 with Polkomtel enjoying higher profitability than PTC and PTK Centertel over the next 5 years" to their offering.
Mobile Operator Forecast on Poland provides over 50 operational and financial metrics for the Polish wireless market and is one of the best forecasts in the industry. We provide five-year forecasts at the operator level going out to 2014. We also provide quarterly historical and forecast data starting in 1Q2003 and ending in 3Q2011. Operators covered for Poland include: PTC (T-Mobile International AG), Polkomtel S.A., PTK Centertel SP. Ltd., and P4 Sp. z o.o. (Play). Our Mobile Operator Forecasts are updated quarterly and are available for one-time delivery or through regular updates.
So what is IEMRs Forecast?
Total wireless subscribers in Poland will rise to 51.5 million in 2014
-- We forecast that the number of mobile subscribers in Poland will
increase from 45.8 million in 2009 to 51.5 million in 2014.
-- Polkomtel will continue to be the largest operator in Poland. We expect
that its subscriber base will increase from 14.9 million in 2009 to 17.3
million in 2014.
-- We also forecast that numbers of subscribers at PTC (T-Mobile), PTK
Centertel, and P4 (Play) will be 15.2 million, 15.9 million and 3
million respectively.
Polkomtel's subscriber market share will be increasing slightly over the next five years
-- We expect that subscriber market shares of PTC (T-Mobile), Polkomtel,
and PTK Centertel will continue to be about 30% each, although we think
that Polkomtel's share will increase slightly over the forecast period.
Our model predicts that, by the end of 2014, the market shares will be
29.5% (PTC), 33.6% (Polkomtel), and 31.0% (PTK Centertel).
-- We expect that the market share of P4 (Play) will remain at about 6%
over the next several years.
ARPUs in the Polish wireless market will be stable from 2010 to 2014
-- Our model forecasts that the industry average monthly ARPU will remain
in the range of PLN 44 - PLN 45 over the next five years.
-- We expect that PTC's monthly ARPU will remain at approximately PLN 47
from 2010 to 2014. We forecast that Polkomtel's ARPUs will continue to
be lower than PTC's; we expect that Polkomtel's monthly ARPU will
decline to PLN 42.81 in 2014.
Polkomtel will continue to enjoy higher profitability than its competitors in the Polish wireless market
-- We forecast that the industry average EBITDA margin (calculated as
EBITDA/reported revenue) will remain at 30% - 31% over the next five
years.
-- We think that Polkomtel will continue to enjoy higher EBITDA margins
than the other mobile operators in Poland. Our model forecasts that
EBITDA margins at Polkomtel, PTC, and PTK Centertel will be 35.5%, 33.1%
and 26.0% in 2014.
Companies Mentioned:
-- PTC (T-Mobile International AG)
-- Polkomtel S.A.
-- PTK Centertel SP. Ltd.
-- P4 Sp. z o.o. (Play)
For more information visit http://www.researchandmarkets.com/research/894941/1q10_poland_mobile
Source: Research and Markets
More Press Releases
View Older Stories-
Research and Markets: Computational Inorganic and Bioinorganic Chemistry
-
EZCORP Names Paul Rothamel President and Announces CEO Succession Plan
-
Acquisition
-
Research and Markets: Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma
-
IIROC: Resumption; Progress Energy Resources Corp.
-
Baldwin Announces Q2 FY2010 Results
-
Devicescape Q4 2009 WiFi Report Results Revealed
-
2Checkout.com, Inc. Increases Flexibility with a Back Office Admin API
-
Notice to the Market: BRMALLS Announces Acquisition of Land Bank in São Bernardo do Campo, São Paulo
-
The New York Times Company Reports 2009 Fourth-Quarter and Full-Year Results
-
Jefferies Further Expands Emerging Markets Platform
-
Polycom Video Infrastructure Innovation Supports Broader Visual Communication and Video-Enabled UC Networks
-
Mart Resources Announces Grant of Stock Options
-
Purina(R) Chef Michael's(R) Declares Dogs The New Valentines In 2010
-
TransGaming Appoints GameTap Creator, Blake Lewin, to Lead GameTree.tv Digital Home Division
-
Research and Markets: Country Industry Forecast - Chinese Building Technologies Industry
-
Research and Markets: Stem Cell Research - Market Trends, Investment Trends and Pipeline Analysis
-
Quaterra and Goldcorp Sign Investment Framework Agreement
-
Aqua America to Report Earnings for Fourth Quarter and Year-End 2009
-
Fifth Third Bank and MasterCard to Provide Next-Generation Corporate Purchasing Solution
-
NMT Medical Reports Preliminary Full Year 2009 Revenues of Approximately $13.2 Million
-
URS Corporation to Host Conference Call to Discuss 2009 Fourth Quarter and Year-End Results
-
Quaterra and Goldcorp Sign Investment Framework Agreement
-
Aastrom Reports Second Quarter Fiscal Year 2010 Financial Results
-
International Aid, Welch Allyn Deliver Vital Medical Equipment to Haiti Quake Zone
-
United Technologies Corp. Advisory to Securities Analysts, Investors and News Media
-
Intelligent Security Systems Appoints Wolfgang Ritter as Director of Sales and Marketing
-
Solar Energy Initiatives, Inc. Creates Jobs and Builds a Solar Economy in South Carolina
-
Mesa Energy Holdings, Inc. Appoints James J. Cerna to the Board of Directors
-
David Loren Corporation Names Walter Johnson Executive Vice President, Sales & Marketing
-
Madison Square Garden, Inc. Becomes a Public Company
-
Cadillac Ventures Announces Initial Spanish Drill Results
-
Far West Mining Ltd.: Four Drill Rigs on Site at Santo Domingo and Copper Metallurgy with Sea Water Confirmed
-
Lyris, Inc., Reports Growth in Second Quarter Revenues Driven by Increased Market Penetration for Its Lyris HQ Platform
-
optionsXpress Reports Key Monthly Performance Metrics for January 2010
-
Bluestreak Technology and SafeNet Join Forces to Enable Secure Premium Movie Solution for Widespread Consumption on Android Devices
-
CMS Bancorp, Inc. Announces Earnings for the Quarter Ended December 31, 2009
-
Immunomedics Appoints Kenneth J. Zuerblis to Board of Directors
-
Flex Fuels Energy, Inc. to Focus Resources on Medical Device Sector
-
ePlus Third Quarter Conference Call Postponed
-
Innodata Isogen Restates Financial Statements to Correct Errors in Deferred Income Tax Accounting
-
CB Richard Ellis Group, Inc. Announces Early Extension of $132.5 Million of Revolver and $24.1 Million of Term Debt Maturities
-
Physicians on Sermo Stunned by FTC Complaint Over Practice Association's Refusal to Accept Medicare Payments
-
China HGS Announces Conference Call to Discuss First Quarter Fiscal Year 2010 Results
-
SpendingPulse: January U.S. Retail Sales Generally Positive
-
EnerNOC Appoints Susan F. Tierney to Board of Directors
-
UniFirst Realizes Significant Cost Savings and Fosters Collaboration With Polycom Telepresence
-
Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session
-
UQM Technologies Propulsion System Selected by Quantum Technologies for Advanced Electric Postal Vehicle
-
CSP Inc. Reports First-Quarter Fiscal 2010 Financial Results
